SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

• tipranavir (Drug)
• ritonavir (Drug)
• Optimized Background Regimen (OBR) (Drug), also known as Nucleoside Reverse Transcriptase Inhibitors (NRTIs),, Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs),, Enfuvirtide,, Maraviroc,, Raltegravir: Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.

Primary outcomes

• Treatment Response at Week 48 [after 48 weeks of treatment]: percentage of participants whose viral load <50 copies/mL at Week 48

Secondary outcomes

• Percentage of Participants Whose Viral Load <50 Copies/mL at Each Visit Including Visits at Weeks 24 and 48 [after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Percentage of Participants Whose Viral Load <400 Copies/mL at Each Visit Including Visits at Weeks 24 and 48 [after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Percentage of Participants Whose ≥1 log10 Drop in Viral Load From Baseline at All Visits, Including Visits at Weeks 24 and 48 [after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Change in Viral Load From Baseline at Each Visit [after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Time to Treatment Failure [after Day 1 of treatment]: For patients who never achieve a confirmed virologic response, time to treatment failure is defined as 0. For patients who achieve a confirmed virologic response, time to treatment failure is the earliest time of either: death, permanent discontinuation of the study drug or loss to follow-up, introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background drug, but not the study drug, or first occurrence of a VL >50 copies/mL at two consecutive measurements after having achieved a VL <50 copies/mL.
• Time to New AIDS or AIDS Related Progression Event or Death [after Day 1 of treatment]
• Change in CD4+ and CD8+ Cell Counts From Baseline at Each Visit Including Visits at Week 24 and Week 48 [after 2 weeks of treatment till Week 48 (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Change in Ratio of CD38+/CD8+ From Baseline to Week 48 [after 2 weeks of treatment till Week 48 (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Tipranavir (TPV) and Ritonavir (RTV) Trough Concentrations at Week 2, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48 [after 2 weeks of treatment till Week 48 (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Patients Adherence With Study Medication Based on Pill Count [after 4 weeks of treatment]
• Occurrence of TPV Inhibitory Quotient (IQ) >60 at Each Visit Where TPV Concentration is Measured [after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Occurrence of TPV Trough Concentration >120 μM [after 2 weeks of treatment (Weeks 2, 4, 8, 12, 24, 36, and 48)]
• Post-dose TPV and RTV Concentrations at Week 4 [Week 4]

Sex: All, ages: 18 Years to any

Inclusion Criteria:

Main inclusion criteria for the study are:

1. HIV-1 infected adults, men and women at least 18 years of age.
2. 3-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI)) treatment-experienced (min of 3-months duration for each class) with resistance to more than one PI (on screening resistance testing). NNRTI-naïve patients who have genotypically documented NNRTI-resistance mutations on past or screening resistance testing would be eligible.
3. CD4+ T lymphocyte count >=50 cells/mm3.
4. HIV-1 viral load >=1,000 copies/mL at screening.
5. The antiretroviral (ARV) study treatment regimen must consist of TPV/r in combo with an optimized background regimen (OBR) of 2-4 agents: N(t)RTIs (NRTI or NtRTI), enfuvirtide (ENF), and/or, where available, a trial approved expanded access program (EAP) investigational agent.
6. Acceptable screening laboratory values that indicate adequate baseline organ function.
7. Acceptable medical history with a chest X-ray without evidence of active disease and an electrocardiogram (ECG) without clinically important abnormalities within one year of the study.
8. A reliable method of barrier contraception will be used by all female patients who are of childbearing potential.

Exclusion Criteria:

Main exclusion criteria for the study are:

1. Known hypersensitivity to the tipranavir (TPV) or ritonavir (RTV).
2. ARV medication naïve.
3. Genotypic resistance to TPV (defined as a TPV mutation score >7).
4. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for at least 7 consecutive days within the month prior to screening.
5. Prior tipranavir use.
6. Inability to adhere to the requirements of the protocol.
7. Patients with prior history of hemorrhagic stroke or intracranial aneurysm.
8. Patients with a history of ischemic stroke, neurosurgery or skull trauma within 4 weeks prior to screening.
9. History of Progressive Multifocal Leukoencephalopathy, Visceral Kaposi's Sarcoma, and/or any malignancy.
10. Any acquired immunodeficiency syndrome (AIDS) defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit.

Participant flow

Outcome results

• Treatment Response at Week 48 (Primary)
• Percentage of Participants Whose Viral Load <50 Copies/mL at Each Visit Including Visits at Weeks 24 and 48 (Secondary)
• Percentage of Participants Whose Viral Load <400 Copies/mL at Each Visit Including Visits at Weeks 24 and 48 (Secondary)
• Percentage of Participants Whose ≥1 log10 Drop in Viral Load From Baseline at All Visits, Including Visits at Weeks 24 and 48 (Secondary)
• Change in Viral Load From Baseline at Each Visit (Secondary)
• Time to Treatment Failure (Secondary)
• Time to New AIDS or AIDS Related Progression Event or Death (Secondary)
• Change in CD4+ and CD8+ Cell Counts From Baseline at Each Visit Including Visits at Week 24 and Week 48 (Secondary)
• Change in Ratio of CD38+/CD8+ From Baseline to Week 48 (Secondary)
• Tipranavir (TPV) and Ritonavir (RTV) Trough Concentrations at Week 2, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48 (Secondary)
• Patients Adherence With Study Medication Based on Pill Count (Secondary)
• Occurrence of TPV Inhibitory Quotient (IQ) >60 at Each Visit Where TPV Concentration is Measured (Secondary)
• Occurrence of TPV Trough Concentration >120 μM (Secondary)
• Post-dose TPV and RTV Concentrations at Week 4 (Secondary)

Adverse events

Time frame: 48 weeks of treatment plus 30 days follow-up

Other adverse events by term

Limitations and caveats: The study was terminated early due to low patient enrollment, and, therefore, no analysis was performed on the primary and secondary endpoints

• Boehringer Ingelheim, Study chair, Boehringer Ingelheim